Which artificial intelligence method will work best with your image data?
Image analysis is an essential part of digital pathology, from research and discovery of targets and biomarkers to understanding the tumor microenvironment to development of novel therapeutics. Whether you need to perform simple tasks or complex analysis of multiplex markers, artificial intelligence can improve performance and facilitate your analysis tasks to unlock the information hidden in image data.
During the last years, deep learning algorithms have revolutionized the quality of analysis and allowed accurate assessment of highly heterogenous and previously challenging tissue structures. In order to best utilize the capabilities that AI methods offer, however, it is important to understand what the terms “artificial intelligence” (AI), “machine learning” (ML), and “deep learning” (DL) really refer to when it comes to image analysis.
This webinar will define the important differences between each term, provide understanding of their roles in image analysis, and help you to decide when to employ each method in your research.
Branden Hopkinson, Product Marketing Manager, Visiopharm
Branden Hopkinson has a Ph.D. in cellular and genetic medicine from the University of Copenhagen, as well as a background in human embryonic stem cells and identification of cell origin for the various types of breast cancer.Message Presenter
Who Should Attend?
- Research Scientist
- Imaging Specialist
- Lab Manager
- Project Leader
- Biomarker Expert
- Principal Investigator
- Biopharma Leader
- Clinical Development Leader
What You Will Learn
In this webinar, participants will learn about:
- The important differences between artificial intelligence, deep learning, and machine learning
- Which artificial intelligence classifiers can be used in the Visiopharm software
- The basics of when to use these classifiers to identify different patterns in data
Visiopharm® is a world leader in AI-driven digital precision pathology software. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and diagnostic pathology labs all over the world use Visiopharm’s technology for tissue-based research and diagnostics. Its solutions use the latest advancements in artificial intelligence and deep learning to make the most comprehensive, highly configurable, and accurate tissue mining tools available on the market today. Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses in more than 38 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in London, England, Munich, Germany, and Westminster, Colorado.